Cell Genesys Inc. and CellPro Inc. annonced Tuesday that they have entered into acollaborative research and development agreement to facilitate the initial clinicalevaluation of genetically engineered anti-HIV T cells developed by Cell Genesys(NASDAQ:CEGE).

The engineered anti-HIV T cells will be modified with Cell Genesys' proprietaryuniversal receptors directed against HIV. CellPro's (NASDAQ:CPRO) Ceprate cell-separationtechnology will be used to increase the efficiency of T cell purification to provide aconsistent product for patient administration.

Cell Genesys of Foster City, Calif., and CellPro of Bothell, Wash., will each retainthe rights to their own technology and products.